Acta Neuropathologica Communications Neuroscience of DiseaseLikeFollowShareThe novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s diseasehttps://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-017-0456-2Share your feedbackQuestions (0)Post questionYour question will be sent privately to Alterity Therapeutics. The company may choose to make this question public.Start the conversationAsk Alterity Therapeutics a question about this update.DiscoverShare your feedbackDiscover